CDSCO Flags Spurious Drugs: 111 Fail Quality Tests in November 2024

CDSCO Flags 2 Drugs as Spurious, Another 111 Fail Quality Test in November 2024: A Wake-Up Call for Drug Safety in India

The Central Drugs Standard Control Organisation (CDSCO), India’s apex regulatory body for pharmaceuticals and medical devices, has issued a concerning report for November 2024. As part of its routine surveillance, CDSCO flagged two drugs as spurious and found another 111 drugs to have failed quality tests. This revelation highlights persistent challenges in ensuring the quality and safety of medicines available in the Indian market.

The findings bring to light critical issues regarding drug regulation, manufacturing practices, and the overall integrity of the pharmaceutical supply chain. The consequences of such lapses are far-reaching, affecting public health, eroding trust in healthcare systems, and tarnishing the image of India as the “pharmacy of the world.” This article explores the details of the CDSCO report, examines the implications of these findings, and discusses the way forward to strengthen drug safety in the country.

What Did the CDSCO Report Reveal?

The CDSCO conducts regular drug quality assessments to ensure compliance with the Drugs and Cosmetics Act, 1940. During its November 2024 review:

• 2 Drugs Were Declared Spurious: Spurious drugs are counterfeit or deliberately mislabeled, posing severe risks to patient safety. These are often manufactured without authorization and may not contain the claimed active ingredients.
• 111 Drugs Failed Quality Standards: These drugs were found substandard due to various reasons, including incorrect potency, contamination, or deviation from prescribed manufacturing standards.

Types of Drugs Involved

The drugs flagged in the report span across multiple categories, including antibiotics, painkillers, antipyretics, and over-the-counter medications. Some were produced by well-known pharmaceutical companies, while others came from lesser-known manufacturers.

Geographical Spread

The substandard drugs were traced to manufacturing facilities across several states, highlighting the need for stricter surveillance at regional levels. States with a higher concentration of flagged drugs include Maharashtra, Himachal Pradesh, and Gujarat, which are key pharmaceutical manufacturing hubs.

Understanding the Terms: Spurious vs Substandard Drugs

The CDSCO categorizes non-compliant drugs into two main types:

1. Spurious Drugs: These are counterfeit and intentionally mislabeled to deceive consumers. Spurious drugs often contain incorrect or no active ingredients, making them extremely dangerous.
2. Substandard Drugs: These fail to meet the quality specifications prescribed by regulatory standards. Causes include improper formulation, contamination, and degradation during storage or transportation.

While spurious drugs indicate deliberate fraud, substandard drugs often result from negligence or lapses in manufacturing and quality control processes.

Why Do Drugs Fail Quality Tests?

The reasons behind drugs failing quality tests are multifaceted and often interlinked:

• Poor Manufacturing Practices: Non-adherence to Good Manufacturing Practices (GMP) is a major contributor. This includes improper hygiene, use of substandard raw materials, and lack of stringent quality control measures.
• Supply Chain Issues: Storage and transportation conditions, such as exposure to high humidity or temperature fluctuations, can degrade drug quality.
• Lax Regulatory Oversight: Inadequate inspections and delayed action against non-compliant manufacturers create an environment where substandard drugs can proliferate.
• Counterfeit Operations: Spurious drugs often originate from illegal manufacturing units that operate without licenses or quality standards.

Impact of Spurious and Substandard Drugs

The presence of spurious and substandard drugs in the market has alarming implications for public health and the pharmaceutical industry.

1. Public Health Risks

• Therapeutic Failure: Substandard drugs may lack the required potency, leading to treatment failures, prolonged illnesses, or complications.
• Toxicity: Contaminated or poorly formulated drugs can cause adverse reactions, organ damage, or even death.
• Antimicrobial Resistance (AMR): Sub-potent antibiotics contribute to the global crisis of antimicrobial resistance, rendering infections harder to treat.

2. Erosion of Trust

Instances of drug quality lapses undermine public confidence in the healthcare system, including doctors, pharmacies, and regulatory bodies.

3. Economic Consequences

• Patient Burden: Consumers bear the financial burden of ineffective or harmful treatments, leading to additional healthcare costs.
• Industry Reputation: India’s status as a global pharmaceutical hub is at stake. Frequent quality issues can deter international buyers and investors, impacting exports.

Regulatory Challenges in Ensuring Drug Safety

Despite being one of the largest producers of pharmaceuticals globally, India faces significant regulatory hurdles in ensuring drug quality.

1. Limited Resources

The CDSCO and state regulatory authorities often face resource constraints, including a lack of skilled inspectors, laboratories, and technological tools to conduct comprehensive surveillance.

2. Fragmented Oversight

India’s pharmaceutical regulatory framework is shared between the CDSCO and state drug controllers, leading to inconsistencies in enforcement and monitoring.

3. Proliferation of Small-Scale Manufacturers

While small and medium enterprises (SMEs) contribute significantly to India’s pharmaceutical production, many struggle to meet GMP standards due to financial and technical constraints.

4. Legal Loopholes

Prolonged legal battles and lenient penalties allow non-compliant manufacturers to continue operations, diluting the deterrent effect of regulatory actions.

Measures Taken by CDSCO to Address Drug Quality Issues

The CDSCO has undertaken several initiatives to enhance drug safety and compliance:

• Routine Surveillance: Regular sampling and testing of drugs from the market.
• Capacity Building: Strengthening laboratories and training personnel to improve the efficiency of quality assessments.
• Stringent Enforcement: Cracking down on illegal manufacturing units and imposing stricter penalties for non-compliance.
• Public Awareness: Educating consumers about the risks of counterfeit and substandard drugs and encouraging them to purchase medicines from licensed pharmacies.

Way Forward: Strengthening Drug Safety in India

The CDSCO’s November 2024 report underscores the need for a comprehensive approach to tackle the issue of spurious and substandard drugs. Here are some key recommendations:

1. Enhancing Regulatory Capacity

• Increase funding for CDSCO and state regulatory authorities to hire more inspectors and establish advanced testing facilities.
• Leverage technology, such as blockchain and AI, to track and monitor the pharmaceutical supply chain.

2. Stricter Compliance with GMP

• Make adherence to GMP mandatory for all manufacturers, regardless of size.
• Conduct frequent and unannounced inspections to ensure compliance.

3. Strengthening Legal Framework

• Impose harsher penalties, including criminal charges, for manufacturers found producing spurious or substandard drugs.
• Expedite legal proceedings to deter repeat offenders.

4. Collaboration with Industry

• Encourage partnerships between regulators and pharmaceutical companies to promote self-regulation and adherence to quality standards.
• Provide financial and technical assistance to SMEs for upgrading their facilities.

5. Consumer Empowerment

• Launch public awareness campaigns about the risks of spurious drugs and the importance of verifying product authenticity.
• Introduce mobile apps and digital tools for consumers to check the legitimacy of medicines.

The CDSCO’s November 2024 findings serve as a stark reminder of the challenges India faces in ensuring drug safety and quality. While the regulatory body’s efforts to identify and flag non-compliant drugs are commendable, the persistent presence of spurious and substandard medicines highlights systemic gaps that need urgent attention.

Strengthening regulatory frameworks, enforcing stricter compliance measures, and fostering collaboration between stakeholders are critical to addressing these issues. As India continues to grow as a global pharmaceutical leader, ensuring the safety and efficacy of its medicines is not just a regulatory imperative but a moral and economic necessity.

By taking decisive action, India can safeguard public health, restore trust in its healthcare system, and reinforce its position as the “pharmacy of the world.”